Real-time Estimate
Other stock markets
|
|
5-day change | 1st Jan Change | |
28.76 USD | -0.12% | -5.74% | -43.95% |
Business Summary
- vaccines (52.4%);
- drugs for the treatment of cancer (15.2%);
- cardiovascular, metabolic and analgesic drugs (11.5%);
- injectable, anti-infectives drugs and active pharmaceutical ingredients (9%);
- drugs for inflammatory and immune diseases (5.5%);
- drugs for rare diseases (4.4%);
- other (2%).
At the end of 2021, the group had more than 39 production sites worldwide.
Net sales are distributed geographically as follows: the United States (36.6%), Europe (22.6%) and other (40.8%).
Number of employees : 83,000
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Biopharma
98.7
%
| 79,557 | 97.9 % | 98,988 | 98.7 % | +24.42% |
Other Business Activities
1.3
%
| 1,731 | 2.1 % | 1,342 | 1.3 % | -22.47% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
42.3
%
| 29,746 | 36.6 % | 42,473 | 42.3 % | +42.79% |
Developed Europe
21.9
%
| 18,336 | 22.6 % | 21,982 | 21.9 % | +19.88% |
Emerging Markets
20.0
%
| 20,701 | 25.5 % | 20,097 | 20.0 % | -2.92% |
Japan
8.0
%
| 7,316 | 9.0 % | 8,026 | 8.0 % | +9.71% |
Developed Rest of World
7.7
%
| 5,190 | 6.4 % | 7,752 | 7.7 % | +49.35% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 61 | 1992 |
David Denton
DFI | Director of Finance/CFO | 58 | 2022 |
Lidia Fonseca
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
Mikael Dolsten
CTO | Chief Tech/Sci/R&D Officer | 64 | 2009 |
Maria Rivas
CTO | Chief Tech/Sci/R&D Officer | 59 | 2022 |
Jeff Settleman
CTO | Chief Tech/Sci/R&D Officer | - | 2019 |
Rady Johnson
CMP | Compliance Officer | 62 | 1993 |
Aida Habtezion
CTO | Chief Tech/Sci/R&D Officer | - | 2020 |
Chief Tech/Sci/R&D Officer | - | 2006 | |
Investor Relations Contact | - | 2021 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 65 | 2020 | |
Ronald Blaylock
BRD | Director/Board Member | 63 | 2017 |
Shantanu Narayen
BRD | Director/Board Member | 59 | 2013 |
Susan Hockfield
BRD | Director/Board Member | 72 | 2020 |
Suzanne Johnson
BRD | Director/Board Member | 66 | 2007 |
Scott Gottlieb
BRD | Director/Board Member | 50 | 2019 |
James Smith
BRD | Director/Board Member | 63 | 2014 |
James R. Quincey
BRD | Director/Board Member | 58 | 2020 |
Director/Board Member | 66 | 2015 | |
Albert Bourla
CEO | Chief Executive Officer | 61 | 1992 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 9,562,413,292 | 5,643,899,525 ( 59.02 %) | 3,916,000,000 ( 40.95 %) | 59.02 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
PFIZER LIMITED 63.92% | 29,243,042 | 63.92% | 1,383,638,919 $ |
HALEON PLC 32.00% | 2,955,063,626 | 32.00% | 11,815,289,997 $ |
3,978,540 | 16.68% | 21,543,794 $ | |
PYXIS ONCOLOGY, INC. 16.03% | 7,032,770 | 16.03% | 11,744,726 $ |
27,349,211 | 15.43% | 646,808,840 $ | |
ALLOGENE THERAPEUTICS, INC. 13.14% | 22,032,040 | 13.14% | 62,130,353 $ |
5,376,344 | 9.86% | 36,021,505 $ | |
HOMOLOGY MEDICINES, INC. 8.65% | 5,000,000 | 8.65% | 5,200,000 $ |
NEXTCURE, INC. 7.08% | 1,970,759 | 7.08% | 2,029,882 $ |
VALNEVA SE 6.88% | 9,549,761 | 6.88% | 54,003,421 $ |
Company contact information

Group companies
Name | Category and Sector |
---|---|
Wyeth Holdings LLC
|
Process Industries - Chemicals: Agricultural
|
Genetics Institute LLC
|
Health Technology - Pharmaceuticals: Major
|
Wyeth Pharmaceuticals LLC
|
Health Technology - Pharmaceuticals: Major
|
Thiakis Ltd.
|
Health Technology - Pharmaceuticals: Major
|
Health Technology - Pharmaceuticals: Major
| |
Pfizer Manufacturing Ireland Unlimited Co.
|
Health Technology - Pharmaceuticals: Major
|
Wyeth Consumer Healthcare, Inc.
|
Health Technology - Pharmaceuticals: Major
|
Ferrosan ApS
|
Health Technology - Pharmaceuticals: Other
|
John Wyeth & Brother Ltd.
|
Health Technology - Pharmaceuticals: Major
|
Sector
Sales per Business
Sales per region
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
28.79USD
Average target price
40.41USD
Spread / Average Target
+40.37%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.95% | 163 B $ | |
+59.95% | 530 B $ | |
+42.05% | 438 B $ | |
-11.67% | 377 B $ | |
-5.69% | 268 B $ | |
-8.52% | 258 B $ | |
-14.13% | 230 B $ | |
+0.79% | 200 B $ | |
-9.98% | 198 B $ | |
+3.62% | 144 B $ |
- Stock
- Equities
- Stock Pfizer, Inc. - Nyse
- Company Pfizer, Inc.